Skip To Content
JEWISH. INDEPENDENT. NONPROFIT.
Fast Forward

Family Needs Help To Fund Gene Therapy For Disease Prevalent in Ashkenazi Jews

Jennie Landsman first noticed something was wrong when her 6-month-old son Benny was still unable to hold up his head. She and her husband Gary took him to multiple specialists. It took months, and the birth of another son, Josh, before finally receiving a devastating answer last August. Their two youngest sons were diagnosed with Canavan Disease, a progressive, fatal brain disorder that develops during infancy and is caused by an inherited genetic abnormality.

Canavan Disease afflicts people of any ethnicity, but is most prevalent among Ashkenazi Jews. An estimated 5,000 Jews are currently affected. Children who have the disease fail to reach developmental milestones. Most do not live past the age of 10.

“You imagine your children outliving you, not that they are going to live this slow, painful, degenerative life, where they get worse and worse as time passes,” Jennie Landsman told the Jewish Week. She has since become vocal about the importance of genetic testing. “I was so uninformed. I never asked about what I was getting tested for.” Had she known that she was a carrier, she would have found alternative methods to improve the chances of having healthy children.

The Landsmans decided to go public to ask for help to fund a new gene therapy that is ready for patient use but does not have enough funding to enter clinical trials.

The Landmans, whose oldest son is healthy, created a GoFundMe page last November, hoping to raise the $1.5 million needed to start a clinical trial. With support from family, friends and even strangers, they are only $200,000 away from their goal.

For additional information, visit their GoFundMe page.

Contact Haley Cohen at [email protected]

A message from our CEO & publisher Rachel Fishman Feddersen

I hope you appreciated this article. Before you go, I’d like to ask you to please support the Forward’s award-winning, nonprofit journalism during this critical time.

At a time when other newsrooms are closing or cutting back, the Forward has removed its paywall and invested additional resources to report on the ground from Israel and around the U.S. on the impact of the war, rising antisemitism and polarized discourse..

Readers like you make it all possible. Support our work by becoming a Forward Member and connect with our journalism and your community.

—  Rachel Fishman Feddersen, Publisher and CEO

Join our mission to tell the Jewish story fully and fairly.

Republish This Story

Please read before republishing

We’re happy to make this story available to republish for free, unless it originated with JTA, Haaretz or another publication (as indicated on the article) and as long as you follow our guidelines. You must credit the Forward, retain our pixel and preserve our canonical link in Google search.  See our full guidelines for more information, and this guide for detail about canonical URLs.

To republish, copy the HTML by clicking on the yellow button to the right; it includes our tracking pixel, all paragraph styles and hyperlinks, the author byline and credit to the Forward. It does not include images; to avoid copyright violations, you must add them manually, following our guidelines. Please email us at [email protected], subject line “republish,” with any questions or to let us know what stories you’re picking up.

We don't support Internet Explorer

Please use Chrome, Safari, Firefox, or Edge to view this site.